Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Novo Nordisk has been accepted back into the fold. Two years after suspending Novo, the Association of the British Pharmaceutical Industry (ABPI) has reinstated the Danish drugmaker after seeing ...

Novo Nordisk A/S (NYSE:NVO) engages in the research and development, manufacture, and distribution of pharmaceutical products.

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks ...

Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent share price underperformance is overdone and offers ...

Novo Nordisk received a boost from a bullish analyst note. The company also continues to be the pacesetter in the limited market for weight-loss drugs. That gravity-defying boost was due in no ...

Novo Nordisk regained full ABPI membership after audits confirmed compliance with governance and promotional standards. The company was suspended in 2023 over a complaint alleging inducements to ...